

MIP-1 β Polyclonal Antibody
Catalog # AP73390**Specification****MIP-1 β Polyclonal Antibody - Product Information**

Application	WB
Primary Accession	P13236
Reactivity	Human
Host	Rabbit
Clonality	Polyclonal

MIP-1 β Polyclonal Antibody - Additional Information**Gene ID** 388372;6351**Other Names**

CCL4; LAG1; MIP1B; SCYA4; C-C motif chemokine 4; G-26 T-lymphocyte-secreted protein; HC21; Lymphocyte activation gene 1 protein; LAG-1; MIP-1-beta(1-69); Macrophage inflammatory protein 1-beta; MIP-1-beta; PAT 744; Protein H400; SIS-gamma; Small-inducible cytokine A4; T-cell activation protein 2; ACT-2

Dilution

WB~~Western Blot: 1/500 - 1/2000. ELISA: 1/20000. Not yet tested in other applications.

Format

Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.09% (W/V) sodium azide.

Storage Conditions

-20°C

MIP-1 β Polyclonal Antibody - Protein Information**Name** CCL4**Synonyms** LAG1, MIP1B, SCYA4**Function**

Monokine with inflammatory and chemokinetic properties. Binds to CCR5. One of the major HIV-suppressive factors produced by CD8+ T- cells. Recombinant MIP-1-beta induces a dose-dependent inhibition of different strains of HIV-1, HIV-2, and simian immunodeficiency virus (SIV). The processed form MIP-1-beta(3-69) retains the abilities to induce down-modulation of surface expression of the chemokine receptor CCR5 and to inhibit the CCR5-mediated entry of HIV-1 in T-cells. MIP-1- beta(3-69) is also a ligand for CCR1 and CCR2 isoform B.

Cellular Location



Secreted.

MIP-1 β Polyclonal Antibody - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

MIP-1 β Polyclonal Antibody - Images



MIP-1 β Polyclonal Antibody - Background

Monokine with inflammatory and chemokinetic properties. Binds to CCR5. One of the major

HIV-suppressive factors produced by CD8+ T-cells. Recombinant MIP-1-beta induces a dose-dependent inhibition of different strains of HIV-1, HIV-2, and simian immunodeficiency virus (SIV). The processed form MIP-1-beta(3-69) retains the abilities to induce down-modulation of surface expression of the chemokine receptor CCR5 and to inhibit the CCR5-mediated entry of HIV-1 in T-cells. MIP-1-beta(3-69) is also a ligand for CCR1 and CCR2 isoform B.